Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end
— PALI-2108 迅速進入治療中度至重度潰瘍性結腸炎的 1 期臨床研究;有望在年底前開始第 1 階段
– Formation of Clinical Advisory Board
— 成立臨床顧問委員會
– Sufficient cash on hand to execute on business plan and achieve significant clinical milestones into 2025
— 手頭有足夠的現金來執行業務計劃並在2025年之前實現重要的臨床里程碑
Carlsbad, CA, March 27, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade", "Palisade Bio" or the "Company"), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.
加利福尼亞州卡爾斯巴德,2024 年 3 月 27 日 — Palisade Bio, Inc. 納斯達克股票代碼:PALI)(“Palisade”、“Palisade Bio” 或 “公司”)是一家專注於爲自身免疫、炎症和纖維化疾病患者開發和推進新療法的臨床前生物製藥公司,今天公佈了其2023年全年財務業績並提供了公司最新情況。
Recent Highlights
近期亮點
- The Company formed its Clinical Advisory Board and appointed preeminent Key Opinion Leaders, Bruce Sands, MD, MS and Florian Rieder, MD;
- The exercise in February 2024, of 3,422,286 previously issued warrants to purchase common stock resulting in gross cash proceeds to the Company of $2.5 million;
- Presentation of positive preclinical data of its lead asset, PALI-2108 at the 2024 Crohn's & Colitis Congress; and
- Giiant Pharma, Inc., the Company's joint development partner, received the second milestone payment to assist in funding PALI-2108 from the US Crohn's and Colitis Foundation, through its IBD Ventures program.
- 公司成立了臨床顧問委員會,並任命了傑出的關鍵意見領袖,醫學博士、醫學博士布魯斯·桑茲和醫學博士弗洛裏安·裏德;
- 2024年2月行使先前發行的3,422,286份普通股認股權證,爲公司帶來250萬美元的總現金收益;
- 在 2024 年克羅恩病和結腸炎大會上公佈其主要資產 PALI-2108 的積極臨床前數據;以及
- 該公司的聯合開發合作伙伴Giiant Pharma, Inc. 通過其 IBD Ventures 計劃從美國克羅恩病和結腸炎基金會獲得了第二筆里程碑式的付款,用於資助 PALI-2108。
"2023 was a transformative year for Palisade Bio as we strategically shifted into the autoimmune, inflammatory, and fibrotic disease space, with the focus on our precision medicine approach in inflammatory bowel disease," commented J.D. Finley, Chief Executive Officer. "As a result of the progress made by our development team, we are on track to launch the Phase 1 study of PALI-2108 by the end of 2024. We are looking forward to the advancement of our lead program to bring our product candidates into clinical trials and to increase our value for all stakeholders."
首席執行官J.D. Finley評論說:“2023年對Palisade Bio來說是變革性的一年,因爲我們戰略性地轉向了自身免疫、炎症和纖維化疾病領域,重點是我們在炎症性腸病方面的精準醫療方法。”“由於我們的開發團隊取得的進展,我們有望在2024年底之前啓動 PALI-2108 的第一階段研究。我們期待着我們的主導項目取得進展,將我們的候選產品納入臨床試驗,並增加我們對所有利益相關者的價值。”
PALI-2108 Development Program
PALI-2108 開發計劃
The Company continues to advance its lead program, PALI-2108, for the treatment of moderate-to-severe ulcerative colitis (UC) toward a Phase 1 clinical study. PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.
該公司繼續將其治療中度至重度潰瘍性結腸炎(UC)的主要項目 PALI-2108 推進到一期臨床研究。PALI-2108 是一種口服、局部作用的結腸特異性磷酸二酯酶4 (PDE4) 抑制劑前藥,正在開發中,用於受UC影響的患者。
Upcoming Target Milestones
即將到來的目標里程碑
- Complete ongoing IND/CTA-enabling tox studies by the end of the second quarter of 2024;
- Complete nonclinical IND/CTA-enabling activities by the end of the third quarter of 2024;
- Submit initial IND/CTA prior to the end of 2024; and
- Initiate Phase 1a/b prior to the end of 2024.
- 在2024年第二季度末之前完成正在進行的支持IND/CTA的毒素研究;
- 在2024年第三季度末之前完成非臨床IND/CTA支持活動;
- 在2024年底之前提交初始IND/CTA;以及
- 在 2024 年底之前啓動第 1a/b 階段。
Precision Medicine Approach
精準醫療方法
Additionally, the Company is in the process of developing a genetic- or biomarker-based precision medicine approach that, if developed, will aid patients and physicians in selecting patients most likely to respond to PDE4 inhibitor therapy with PALI-2108. The Company is working with a strategic collaborator on development and has completed curation of a pipeline including over 1600 UC patients clinical and biomarker data and is in ongoing discussions with potential partners with access to additional patient data to support development of an FDA-approved test. The Company plans to leverage this expertise and infrastructure to fuel a growing pipeline of validated and high-priority autoimmune, inflammatory, and fibrotic disease product candidates.
此外,該公司正在開發一種基於遺傳或生物標誌物的精準醫療方法,該方法如果開發出來,將幫助患者和醫生選擇最有可能對 PALI-2108 PDE4 抑制劑療法產生反應的患者。該公司正在與戰略合作方合作進行開發,並已完成了包括1600多名UC患者臨床和生物標誌物數據的管道策劃,並且正在與潛在合作伙伴進行討論,以獲取更多患者數據,以支持FDA批准的測試的開發。該公司計劃利用這種專業知識和基礎設施爲不斷增長的經過驗證和高度優先的自身免疫性、炎症和纖維化疾病候選產品提供燃料。
Summary of Financial Results for the Year Ended December 31, 2023
截至2023年12月31日止年度的財務業績摘要
As of December 31, 2023, the Company had cash, cash equivalents and restricted cash of $12.5 million. The Company believes it has sufficient cash to fund its currently planned operations into the first quarter of 2025.
截至2023年12月31日,該公司的現金、現金等價物和限制性現金爲1,250萬美元。該公司認爲,它有足夠的現金爲其目前計劃到2025年第一季度的運營提供資金。
Net operating loss was $13.1 million for the year ended December 31, 2023 compared to $15.7 million for the year ended December 31, 2022. Included in the net operating loss for the year ended December 31, 2023 was license revenue of $0.3 million, of which there was none in 2022, and restructuring costs of $0.2 million in 2023, compared to restructuring costs of $0.4 million in 2022.
截至2023年12月31日止年度的淨營業虧損爲1,310萬美元,而截至2022年12月31日的年度淨營業虧損爲1,570萬美元。截至2023年12月31日止年度的淨營業虧損中包括30萬美元的許可收入,其中2022年沒有許可收入,2023年的重組成本爲20萬美元,而2022年的重組成本爲40萬美元。
Research and development expenses were $6.9 million for the year ended December 31, 2023, an increase of $0.3 million, or approximately 5% compared to the year ended December 31, 2022. The year-over-year increase is attributable to increased costs associated with the Giiant License Agreement, which we entered into on September 1, 2023, as well an increase in employee-related costs and employee recruiting costs, which were partially offset by a decrease in costs directly related to our development of LB1148, which we ceased in August of 2023.
截至2023年12月31日的財年,研發費用爲690萬美元,與截至2022年12月31日的年度相比增加了30萬美元,增長了約5%。同比增長歸因於與我們於 2023 年 9 月 1 日簽訂的 Giiant 許可協議相關的成本增加,以及員工相關成本和員工招聘成本的增加,但這些費用被與開發 LB1148 直接相關的成本減少部分抵消,我們已於 2023 年 8 月停止開發。
General and administrative expenses decreased from $8.8 million for the year ended December 31, 2022 to $6.2 million for the year ended December 31, 2023. The decrease of $2.6 million, or 26%, was primarily as a result of cost-saving opportunities implemented by us in the third and fourth quarters of 2022, including those associated with the 2022 Cost-Reduction Plan. General and administrative employee compensation costs for the year ended December 31, 2023 decreased by approximately $1.4 million compared to the year ended December 31, 2022, primarily due to an approximately $0.9 million decrease in salaries and benefits and an approximately $0.5 million decrease in stock-based compensation expense. Other decreases in general and administrative expenses for the year ended December 31, 2023 compared to the year ended December 31, 2022 include: (i) an approximately $0.3 million decrease in professional fees, including accounting and legal fees and financial printing costs, (ii) an approximately $0.3 million decrease in investor and public relations costs and shareholder services costs, (iii) an approximately $0.2 million decrease in consultants and contract labor costs, (iv) an approximately $0.2 million decrease in general and administrative employee recruiting costs, and (v) an approximately $0.2 million decrease in insurance costs.
一般和管理費用從截至2022年12月31日止年度的880萬美元下降到截至2023年12月31日止年度的620萬美元。減少260萬美元,下降26%,主要是由於我們在2022年第三和第四季度實施了成本節約機會,包括與2022年成本削減計劃相關的機會。與截至2022年12月31日的年度相比,截至2023年12月31日的年度的一般和管理員工薪酬成本減少了約140萬美元,這主要是由於工資和福利減少了約90萬美元,股票薪酬支出減少了約50萬美元。與截至2022年12月31日的年度相比,截至2023年12月31日的年度一般和管理費用的其他減少包括:(i)專業費用減少了約30萬美元,包括會計和律師費以及財務印刷成本;(ii)投資者和公共關係成本以及股東服務成本減少約30萬美元;(iii)顧問和合同勞動力成本減少約20萬美元;(iv)減少約20萬美元一般僱員和行政員工招聘費用, 以及 (v) 保險費用減少約20萬美元.
About Palisade Bio
Palisade Bio is a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
關於 Palisade Bio
Palisade Bio是一家臨床前生物製藥公司,專注於爲自身免疫、炎症和纖維化疾病患者開發和推進新型療法。該公司認爲,通過對新療法使用靶向方法,它將改變治療格局。欲了解更多信息,請前往 www.palisadebio.com。
Forward Looking Statements
This communication contains "forward-looking" statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company's ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company's ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 26, 2024. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
前瞻性陳述
就1995年《私人證券訴訟改革法》的安全港條款而言,本通信包含 “前瞻性” 陳述。前瞻性陳述包括有關公司意圖、信念、預測、前景、分析或當前預期的陳述,其中包括:我們的現金流範圍;我們成功開發許可技術的能力;對候選產品市場規模和增長潛力的估計,以及我們爲這些市場提供服務的能力,包括所產生的任何潛在收入;美國(美國)和外國未來的監管、司法和立法變化或發展,以及這些變化的影響;我們維持證券在納斯達克上市的能力;我們在美國和其他市場建立商業基礎設施的能力;我們在競爭激烈的行業中進行有效競爭的能力;我們識別和認證製造商提供原料藥和製造藥品的能力;我們簽訂商業供應協議的能力;已經或可能出現的競爭技術的成功;我們吸引和留住關鍵科學或管理人員的能力;我們有關估計的準確性支出、未來收入、資本要求和額外融資需求;我們獲得運營資金的能力;我們吸引合作者和戰略伙伴關係的能力;以及 COVID-19 疫情或任何全球事件對我們的業務、運營和供應的影響。本通信中包含的任何非歷史事實陳述的陳述均可被視爲前瞻性陳述。這些前瞻性陳述基於公司當前的預期。前瞻性陳述涉及風險和不確定性。由於這些風險和不確定性,公司的實際業績和事件發生時間可能與此類前瞻性陳述中的預期存在重大差異,其中包括但不限於公司推進其非臨床和臨床項目的能力、不確定和耗時的監管批准程序;以及公司獲得額外融資以資助其候選產品的未來運營和開發的能力。其他風險和不確定性可以在公司於2024年3月26日向美國證券交易委員會(“SEC”)提交的截至2023年12月31日財年的10-K表年度報告中找到。這些前瞻性陳述僅代表截至本文發佈之日,公司明確表示沒有義務或承諾公開發布此處包含的任何前瞻性陳述的任何更新或修訂,以反映公司對這些前瞻性陳述的預期的任何變化或任何此類陳述所依據的事件、條件或情況的任何變化。
Investor Relations Contact
投資者關係聯繫人
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com
JTC Team, LLC
珍妮·托馬斯
833-475-8247
PALI@jtcir.com
Palisade Bio, Inc.
Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share amounts)
Palisade Bio, Inc.
合併資產負債表(未經審計)
(以千計,股票和每股金額除外)
December 31, | ||||||||
2023 | 2022 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 12,432 | $ | 12,383 | ||||
Prepaid expenses and other current assets | 896 | 2,350 | ||||||
Total current assets | 13,328 | 14,733 | ||||||
Restricted cash | 26 | 26 | ||||||
Property and equipment, net | 10 | 10 | ||||||
Operating lease right-of-use asset | 198 | 300 | ||||||
Other noncurrent assets | 490 | 694 | ||||||
Total assets | $ | 14,052 | $ | 15,763 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 698 | $ | 1,759 | ||||
Accrued liabilities | 831 | 574 | ||||||
Accrued compensation and benefits | 778 | 486 | ||||||
Current portion of operating lease liability | 121 | 105 | ||||||
Insurance financing debt | 158 | 88 | ||||||
Total current liabilities | 2,586 | 3,012 | ||||||
Warrant liability | 2 | 61 | ||||||
Contingent consideration obligation | 61 | – | ||||||
Operating lease liability, net of current portion | 90 | 211 | ||||||
Total liabilities | 2,739 | 3,284 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at December 31, 2023 and December 31, 2022 | 2 | 2 | ||||||
Common stock, $0.01 par value; 280,000,000 shares authorized; 9,270,894 and 2,944,306 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 93 | 30 | ||||||
Additional paid-in capital | 132,724 | 121,637 | ||||||
Accumulated deficit | (121,506) | (109,190) | ||||||
Total stockholders' equity | 11,313 | 12,479 | ||||||
Total liabilities and stockholders' equity | $ | 14,052 | $ | 15,763 |
十二月三十一日 | ||||||||
2023 | 2022 | |||||||
資產 | ||||||||
流動資產: | ||||||||
現金和現金等價物 | $ | 12,432 | $ | 12,383 | ||||
預付費用和其他流動資產 | 896 | 2,350 | ||||||
流動資產總額 | 13,328 | 14,733 | ||||||
限制性現金 | 26 | 26 | ||||||
財產和設備,淨額 | 10 | 10 | ||||||
經營租賃使用權資產 | 198 | 300 | ||||||
其他非流動資產 | 490 | 694 | ||||||
總資產 | $ | 14,052 | $ | 15,763 | ||||
負債和股東權益 | ||||||||
流動負債: | ||||||||
應付賬款 | $ | 698 | $ | 1,759 | ||||
應計負債 | 831 | 574 | ||||||
應計薪酬和福利 | 778 | 486 | ||||||
經營租賃負債的當前部分 | 121 | 105 | ||||||
保險融資債務 | 158 | 88 | ||||||
流動負債總額 | 2,586 | 3,012 | ||||||
認股權證責任 | 2 | 61 | ||||||
或有對價義務 | 61 | — | ||||||
經營租賃負債,扣除流動部分 | 90 | 211 | ||||||
負債總額 | 2,739 | 3,284 | ||||||
承付款和意外開支 | ||||||||
股東權益: | ||||||||
A系列可轉換優先股,面值0.01美元, 已授權 7,000,000 股;已發行 200,000 股 截至 2023 年 12 月 31 日和 2022 年 12 月 31 日的未繳款項 | 2 | 2 | ||||||
普通股,面值0.01美元;授權2.8億股; 已發行和流通的9,270,894和2,944,306股股票 分別於 2023 年 12 月 31 日和 2022 年 12 月 31 日 | 93 | 30 | ||||||
額外的實收資本 | 132,724 | 121,637 | ||||||
累計赤字 | (121,506) | (109,190) | ||||||
股東權益總額 | 11,313 | 12,479 | ||||||
負債和股東權益總額 | $ | 14,052 | $ | 15,763 |
Palisade Bio, Inc.
Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)
Palisade Bio, Inc.
合併運營報表(未經審計)
(以千計,股票和每股金額除外)
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
License revenue | $ | 250 | $ | – | ||||
Operating expenses: | ||||||||
Research and development | 6,893 | 6,547 | ||||||
General and administrative | 6,202 | 8,764 | ||||||
Restructuring costs | 225 | 410 | ||||||
Total operating expenses | 13,320 | 15,721 | ||||||
Loss from operations | (13,070) | (15,721) | ||||||
Other income (expense): | ||||||||
Interest expense | (15) | (13) | ||||||
Other income | 785 | 2,584 | ||||||
Loss on issuance of warrants | – | (1,110) | ||||||
Total other income, net | 770 | 1,461 | ||||||
Net loss | $ | (12,300) | $ | (14,260) | ||||
Net loss available to common stockholders | $ | (12,316) | $ | (14,548) | ||||
Basic and diluted weighted average shares used in computing basic and diluted net loss per common share | 6,840,213 | 880,311 | ||||||
Basic and diluted net loss per common share | $ | (1.80) | $ | (16.53) |
截至12月31日的財年 | ||||||||
2023 | 2022 | |||||||
許可證收入 | $ | 250 | $ | — | ||||
運營費用: | ||||||||
研究和開發 | 6,893 | 6,547 | ||||||
一般和行政 | 6,202 | 8,764 | ||||||
重組成本 | 225 | 410 | ||||||
運營費用總額 | 13,320 | 15,721 | ||||||
運營損失 | (13,070) | (15,721) | ||||||
其他收入(支出): | ||||||||
利息支出 | (15) | (13) | ||||||
其他收入 | 785 | 2,584 | ||||||
發行認股權證的損失 | — | (1,110) | ||||||
其他收入總額,淨額 | 770 | 1,461 | ||||||
淨虧損 | $ | (12,300) | $ | (14,260) | ||||
普通股股東可獲得的淨虧損 | $ | (12,316) | $ | (14,548) | ||||
計算中使用的基本和攤薄後的加權平均份額 普通股每股基本淨虧損和攤薄淨虧損 | 6,840,213 | 880,311 | ||||||
普通股每股基本虧損和攤薄後淨虧損 | $ | (1.80) | $ | (16.53) |
Palisade Bio, Inc.
Consolidated Statements of Cash Flows (Unaudited)
(in thousands, except share and per share amounts)
Palisade Bio, Inc.
合併現金流量表(未經審計)
(以千計,股票和每股金額除外)
Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
Net loss | $ | (12,300) | $ | (14,260) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 4 | 3 | ||||||
Noncash operating lease expense | 102 | 164 | ||||||
Loss on issuance of warrants | – | 1,110 | ||||||
Fair value of contingent consideration obligation | 204 | – | ||||||
Change in fair value of warrant liabilities | (59) | (2,426) | ||||||
Stock-based compensation and related charges | 624 | 1,032 | ||||||
Other | (108) | (233) | ||||||
Changes in operating assets and liabilities: | ||||||||
Prepaid and other current assets and other noncurrent assets | 705 | 1,027 | ||||||
Accounts payable and accrued liabilities | (492) | 399 | ||||||
Accrued compensation | 292 | (25) | ||||||
Operating lease liabilities | (105) | (151) | ||||||
Net cash used in operating activities | (11,133) | (13,360) | ||||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | (4) | (10) | ||||||
Net cash used in investing activities | (4) | (10) | ||||||
Cash flows from financing activities: | ||||||||
Payments on insurance financing debt | (391) | (790) | ||||||
Proceeds from issuance of common stock and warrants | 9,419 | 14,401 | ||||||
Proceeds from the exercise of warrants | 2,758 | 2,274 | ||||||
Payment of equity issuance costs | (617) | (627) | ||||||
Proceeds from issuance of common stock under Employee Stock Purchase Plan | 17 | – | ||||||
Net cash provided by financing activities | 11,186 | 15,258 | ||||||
Net increase in cash, cash equivalents and restricted cash | 49 | 1,888 | ||||||
Cash, cash equivalents and restricted cash, beginning of year | 12,409 | 10,521 | ||||||
Cash, cash equivalents and restricted cash, end of year | $ | 12,458 | $ | 12,409 | ||||
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets: | ||||||||
Cash and cash equivalents | $ | 12,432 | $ | 12,383 | ||||
Restricted cash | 26 | 26 | ||||||
Total cash, cash equivalents and restricted cash | $ | 12,458 | $ | 12,409 |
截至12月31日的財年 | ||||||||
2023 | 2022 | |||||||
淨虧損 | $ | (12,300) | $ | (14,260) | ||||
爲使淨虧損與經營活動中使用的淨現金相一致而進行的調整: | ||||||||
折舊 | 4 | 3 | ||||||
非現金經營租賃費用 | 102 | 164 | ||||||
發行認股權證的損失 | — | 1,110 | ||||||
或有對價債務的公允價值 | 204 | — | ||||||
認股權證負債公允價值的變化 | (59) | (2,426) | ||||||
股票薪酬和相關費用 | 624 | 1,032 | ||||||
其他 | (108) | (233) | ||||||
運營資產和負債的變化: | ||||||||
預付資產和其他流動資產以及其他非流動資產 | 705 | 1,027 | ||||||
應付賬款和應計負債 | (492) | 399 | ||||||
應計補償 | 292 | (25) | ||||||
經營租賃負債 | (105) | (151) | ||||||
用於經營活動的淨現金 | (11,133) | (13,360) | ||||||
來自投資活動的現金流: | ||||||||
購買財產和設備 | (4) | (10) | ||||||
用於投資活動的淨現金 | (4) | (10) | ||||||
來自融資活動的現金流: | ||||||||
保險融資債務的付款 | (391) | (790) | ||||||
發行普通股和認股權證的收益 | 9,419 | 14,401 | ||||||
行使認股權證的收益 | 2758 | 2,274 | ||||||
支付股票發行成本 | (617) | (627) | ||||||
根據員工股票購買計劃發行普通股的收益 | 17 | — | ||||||
融資活動提供的淨現金 | 11,186 | 15,258 | ||||||
現金、現金等價物和限制性現金淨增加 | 49 | 1,888 | ||||||
現金、現金等價物和限制性現金,年初 | 12,409 | 10,521 | ||||||
現金、現金等價物和限制性現金,年底 | $ | 12,458 | $ | 12,409 | ||||
現金、現金等價物和限制性現金與資產負債表的對賬: | ||||||||
現金和現金等價物 | $ | 12,432 | $ | 12,383 | ||||
限制性現金 | 26 | 26 | ||||||
現金、現金等價物和限制性現金總額 | $ | 12,458 | $ | 12,409 |